Eliem Therapeutics (ELYM) will pause all further development of ETX-155
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
February 9, 2023 4:01 PM ESTCompany to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123
Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment
Implementing corporate reorganization to extend cash runway into 2027
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (Eliem or the Company), a... More
